Announcement of Ningbo Menova Pharmaceutical Co., Ltd. on increasing capital to its wholly-owned subsidiary Ningbo Menohua Tiankang Pharmaceutical Co., Ltd.
Announcement of Ningbo Menova Pharmaceutical Co., Ltd. on the wholly-owned subsidiary obtaining a duloxetine hydrochloride enteric capsule drug registration certificate
Announcement of Ningbo Menova Pharmaceutical Co., Ltd. on the holding subsidiary arginine perindopril API passing the CDE technical review
Legal Opinion of Guangfa Law Firm, Shanghai Regarding the First Extraordinary General Meeting of Shareholders of Ningbo Menovo Pharmaceutical Co., Ltd. in 2024.
Announcement of resolutions of the first extraordinary general meeting of shareholders of Ningbo Menovo Pharmaceutical Co., Ltd. in 2024.
Materials for the first extraordinary general meeting of shareholders of Ningbo Menovo Pharmaceutical Co., Ltd. in 2024.
Announcement Regarding Revision of Long-term Loan Contract with Subsidiaries and Related Parties, Extension of Guarantee Period Provided by the Company and Authorization to Management to Sign Related Documents.
Announcement of Ningbo Menovo Pharmaceutical Co., Ltd.'s additional temporary proposal for the first extraordinary shareholders meeting in 2024.
Notice of the convening of the first extraordinary shareholder meeting of Ningbo Menovo Pharmaceutical Co., Ltd. in 2024.
Announcement from Ningbo Menovo Pharmaceutical Co., Ltd. on the re-examination and temporary suspension of part of the raised capital investment projects, as well as the temporary adjustment of the idle site use of the raised investment projects.
Ningbo Menovo Pharmaceutical: Announcement on the completion of the industrial and commercial registration change and the replacement of the business license by Ningbo Menovo Pharmaceutical Co., Ltd.
Announcement on the completion of the industrial and commercial registration change and the replacement of the business license by Ningbo Menovo Pharmaceutical Co., Ltd.
Announcement by Ningbo Menovo Pharmaceutical Co., Ltd. on its wholly-owned subsidiary obtaining the registration certificate of propofol propofol tablets.
Announcement of the Adjustment of Conversion Price of Ningbo Menovo Pharmaceutical Co., Ltd.'s Convertible Bonds due to Equity Distribution
Announcement of Debt-for-Equity Swaps and Shareholder Changes of Ningbo Menovo Pharmaceutical Co., Ltd. Convertible Bonds
Announcement of Ningbo Menovo Pharmaceutical Co., Ltd.'s wholly-owned subsidiary obtaining the registration certificate for pharmaceutical Daclatasvir tablets.
Announcement on the suspension of the conversion of "Menovo Convertible Bonds" and the adjustment of conversion prices in the implementation of equity distribution for the year 2023 by Ningbo Menovo Pharmaceutical Co., Ltd.
The Articles of Association of Ningbo Menovo Pharmaceutical Co., Ltd. (revised in June 2024).
Announcement of Ningbo Menovo Pharmaceutical Co., Ltd. on the revision of the company's articles of association.
2021 Ningbo Menovo Pharmaceutical Co., Ltd. public issuance of convertible enterprise bonds 2024 tracking rating report.
No Data